FGFR2 and neoplasm: The US Food and Drug Administration has approved several treatments for specific genomic mutations following the time period reported in this study, including pembrolizumab in tumor mutational burden–high, microsatellite instability–high, or mismatch repair–deficient solid tumors;19,20 pemigatinib and infigratinib in previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements;21, 22, 23 and ivosidenib in previously treated, locally advanced, or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation.24